High Expression of B7-H2 or B7-H3 is Associated with Poor Prognosis in Hepatocellular Carcinoma

Jingfeng Liu,Xiaolong Liu,Youshi Zheng,Naishun Liao,Bixing Zhao

DOI: https://doi.org/10.1016/j.hpb.2019.10.2001

IF: 3.842

2019-01-01

HPB

Abstract:Introduction: B7 family members have been associated with the signaling transduction pathways underlying tumor immune evasion in hepatocellular carcinoma. Method: Herein, the associations of clinical characteristics of HCC patients with the expression of B7-H2 and B7-H3 were analyzed. A total of 63 formalin-fixed and paraffin-embedded HCC tissues were collected to be used as a tissue microarray. Following this, the association between B7-H2/B7-H3 and the prognosis of HCC patients was analyzed with Pearson's χ2 test, the Kaplan-Meier method and receiver operating characteristic curve analysis. Result: The results demonstrated that B7-H2 expression was significantly associated with recurrence (within 1 year) in HCC patients (P<0.01), and that B7-H3 expression was associated with recurrence (within 1 year), metastasis and 2 year overall survival rate in HCC patients (P<0.01, P=0.036 and P=0.016, respectively). In addition, the combination of B7-H2 and B7-H3 expression was also associated with prognostic factors including recurrence (within 1 year) and survival rate (within 2 years) in HCC patients. In particular, an increased area under the curve was achieved when considering the combination of B7-H2 and B7-H3 expression when compared with that for α-fetoprotein. Conclusion: Taken together, these results indicated that B7-H2 and/or B7-H3-positive expression indicates a poor clinical outcome for patients, and the combination of B7-H2 and B7-H3 may be a preferential prognostic biomarker in HCC patients.